Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul;94(29):e1211.
doi: 10.1097/MD.0000000000001211.

Increased Risk of Chronic Fatigue Syndrome Following Atopy: A Population-Based Study

Tse-Yen Yang  1 , Haung-Tsung Kuo, Hsuan-Ju Chen, Chih-Sheng Chen, Wei-Ming Lin, Shin-Yi Tsai, Chua-Nan Kuo, Chia-Hung Kao
Affiliations

Increased Risk of Chronic Fatigue Syndrome Following Atopy: A Population-Based Study

Tse-Yen Yang et al. Medicine (Baltimore). 2015 Jul.

Abstract

Several hypotheses have been proposed to explain the etiopathogenesis of chronic fatigue syndrome (CFS), including immune dysregulation. However, few population-based prospective cohort studies have been conducted on CFS and atopy. We investigated the relationship between atopy and CFS by using a population-based cohort study. In this prospective, population-based cohort study of the National Health Insurance Research Database, we identified 42,558 patients with atopy and 170,232 patients without atopy from 2005 to 2007 with follow-up to 2011. The incidence rates and risks for CFS were estimated using Cox proportion hazards regression. The overall incidence rate of CFS was higher in the atopy cohort compared with the nonatopy cohort (1.37 versus 0.87 per 1000 person-year), with an adjusted hazard ratio of 1.48 (95% confidence interval 1.30-1.69). The risk of CFS in the atopy cohort increased 1.47- to 1.50-fold for each nonexisting comorbidity. Patients with numerous atopic symptoms exhibited a biological gradient of increasing risk for CFS, and the risk changed significantly after adjustment for age, sex, and comorbidities, increasing from 1.46- to 2.59-fold. We revealed that atopy is associated with CFS, particularly in patients with numerous atopic syndromes. The actual mechanism for CFS development in patients with atopy remains unclear and requires further investigation. We recommend researching the subsequent fatigue symptom in patients with atopy, particularly those with multiple atopic syndromes.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Cumulative incidence curves of chronic fatigue syndrome for atopic syndrome and control groups.
See this image and copyright information in PMC

References

    1. Chronic Fatigue Syndrome (CFS), Centers for Disease Control and Prevention. http://www.cdc.gov/cfs/causes/index.html Accessed May 14 2012.
    1. Straus SE, Dale JK, Wright R, et al. Allergy and the chronic fatigue syndrome. J Allergy Clin Immunol 1988; 81:791–795. - PubMed
    1. Conti F, Magrini L, Priori R, et al. Eosinophil cationic protein serum levels and allergy in chronic fatigue syndrome. Allergy 1996; 51:124–127. - PubMed
    1. Steinberg P, McNutt BE, Marshall P, et al. Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome. J Allergy Clin Immunol 1996; 97:119–126. - PubMed
    1. Borish L, Schmaling K, DiClementi JD, et al. Chronic fatigue syndrome: identification of distinct subgroups on the basis of allergy and psychologic variables. J Allergy Clin Immunol 1998; 102:222–230. - PubMed

Publication types